Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer |
| |
| Affiliation: | 1. Laboratory of Mathematical Chemistry (LMC), As. Zlatarov University, Bourgas, Bulgaria;2. The University of Tennessee, College of Veterinary Medicine, Knoxville, TN 37996-4500, USA;1. The Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, 300060, China;2. The Department of Thyroid and Breast Surgery, Nanyang First People''s Hospital, Henan, 473000, China;3. The Department of Obstetrics and Gynecology, The Central Hospital of Enshi, Hubei, 445000, China;1. Center for Liver Disease and Transplantation, Division of Digestive and Liver Diseases, Columbia University Irving Medical Center, New York, New York;3. Division of Digestive and Liver Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York;4. Liver Center, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts;5. Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden;7. Unit of Hepatology, Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden;12. Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden;8. Department of Pediatrics, Örebro University Hospital, Örebro, Sweden;1. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark;2. Danish Centre for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg University Hospital, Denmark;3. Department of Vascular Surgery, Viborg Regional Hospital, Viborg, Denmark;4. Department of Vascular Surgery, Rigshospitalet, Copenhagen University, Copenhagen, Denmark;5. Department of Vascular Surgery, Aalborg University Hospital, Aalborg, Denmark;6. Department of Vascular and Endovascular Surgery, Asklepios Clinic Wandsbek, Asklepios Medical School, Hamburg, Germany;7. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark;8. Research Unit of Cardiac, Thoracic, and Vascular Surgery, Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark and Odense University Hospital, Odense, Denmark |
| |
| Abstract: | ![]()
Favorable results have been reported for the treatment of advanced colorectal cancer with the combination of 5-fluorouracil (5-FU) and leucovorin (LV). In these investigations the highest response rates were obtained in non-pretreated patients. In the present study, 22 patients with primary or acquired resistance to single-agent 5-FU and documented progressive disease on 5-FU were given a bolus injection of LV at a dose of 200 mg/m2, 1 h prior to a 2 h infusion of 5-FU at a dose of 370–770 mg/m2 on 5 consecutive days, and this was repeated every 3 weeks. Whenever possible the dose of 5-FU was escalated to find the maximum tolerable dose. No objective response was observed. Five patients had short-lasting stable disease. Despite 5-FU dose escalation, toxicity was acceptable. One patient developed 5-FU-related angina pectoris with EKG changes. It is concluded that in the schedule used, combined LV/5-FU treatment is ineffective for patients with 5-FU-resistant advanced colorectal cancer. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
